The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...